Warning: Undefined variable $count in /home/seniorca/public_html/wp-content/themes/divi-news-child-healthcare/index.php on line 40

Warning: Undefined variable $count in /home/seniorca/public_html/wp-content/themes/divi-news-child-healthcare/index.php on line 121

UPMC Acquires Local Hospice Provider

by | Mar 23, 2015 2:08 pm | Home Health & Hospice

The University of Pittsburgh Medical Center (UPMC) has been busy this year, with two acquisitions and a “significant investment,” after 18 months off the M&A circuit. This month’s acquisition was Family Hospice and Palliative Care, also in Pittsburgh. The company is the state’s largest not-for-profit medical services provider for people with terminal illness. UPMC also made an undisclosed investment in Health Fidelity, a Palo Alto-based technology company with a “risk adjustment solution” that was deployed by UPMC Health Plan last year. UPMC’s previous acquisition was Jameson Health System in New Castle, Pennsylvania, announced in February. Read More »

Endo Tries to Upstage Valeant’s Bid for Salix

by | Mar 16, 2015 8:21 pm | Pharmaceuticals

It’s not over until the fat check arrives. That’s the story of Salix Pharmaceuticals (NASDAQ: SLXP), which last month accepted Valeant Pharmaceuticals’ (NYSE: VRX) $10.1 billion acquisition offer. Valeant thought it had snatched victory from Shire plc (NASDAQ: SHPG) and Endo International plc (NASDAQ: ENDP), which were also readying bids for the troubled Salix. Endo apparently wasn’t daunted, and last week came back with a cash and stock bid of approximately $11.1 billion. Stay tuned. Read More »

Year’s Biggest Billion-Dollar Deals Top $64 Billion

by | Mar 16, 2015 8:16 pm | Biotechnology, Pharmaceuticals

Already in 2015, we’ve recorded 11 billion-dollar-plus deals, for a total of $64.4 billion. Thanks to the $21 billion AbbVie (NYSE: ABBV) bid for Pharmacyclics (NASDAQ: PCYC), the biotechnology sector accounted for $27.5 billion of those big deals. Pharmaceuticals, with four billion-plus transactions, still ranks first, with combined spending of $30.45 billion.  Read More »

Doc Group Acquisitions Pick Up

by | Mar 16, 2015 7:56 pm | Hospitals

After a few quiet weeks with no announcements, the Physician Medical Group sector got busy. Sheridan Healthcare, a subsidiary of AmSurg Corp. (NASDAQ: AMSG), acquired Radiology Associates of Hollywood (Florida), which handles radiology services for 12 hospitals and other facilities in Broward County. US Anesthesia Partners picked up another Texas-based practice, Excel Anesthesia, P.A., which it will merge into Pinnacle Anesthesia Consultants, one of its founding partners. Then Partners HealthCare System, which was spurned by the Massachusetts Attorney General in its bid for South Shore Hospital, turned around and angered the AG once again by acquiring Harbor Medical Associates in South... Read More »

NKKR Buys a Texas Air Ambulance Company

by | Mar 16, 2015 7:45 pm | Other Services

Air ambulance companies are not on most investors’ radar, yet at least one acquisition of this ancillary healthcare service pops up about once a year. This year’s deal came early, as KKR & Co. LP (NYSE: KKR) paid an undisclosed amount for Air Medical, an air ambulance company based in Lewisville, Texas. It was owned by affiliates of private equity firms Bain Capital and Brockway Moran & Partners. Last year’s air ambulance deal was announced in August, when privately held REACH Air Medical Services of Santa Rosa, California acquired Emergency Airlift Service in North Bend, Oregon. No prices were disclosed, of course. In fact, the last price we recorded for an air ambulance company... Read More »

AbbVie Wins Pharmacyclics

by | Mar 9, 2015 7:33 pm | Pharmaceuticals

Everybody hates a winner, it seems. Last week’s announcement that AbbVie Inc. (NYSE: ABBV) won the bidding war for Pharmacyclics Inc. (NASDAQ: PCYC) had many analysts shaking their heads in disbelief. The consternation was over the price, which at $261.25 per share for PCYC came to approximately $21 billion, about 27.8x revenue and 165.6x EBITDA. The real prize for AbbVie is Imbruvica, an effective treatment against a form of leukemia and other diseases that Pharmacyclics is marketing under an agreement with Johnson & Johnson (NYSE: JNJ). J&J and Pfizer (NYSE: PFE) were also in the final round of bidders. AbbVie’s shares fell nearly 6% on March 5, the day after the announcement,... Read More »

What U.S. Health Care Companies Are Buying Overseas

by | Mar 9, 2015 7:27 pm | Biotechnology, Pharmaceuticals

We’re hosting a webinar on March 12 called  Cross-Border M&A: Opportunities and Issues. As a run-up to it, here’s a peek at what U.S. health care companies have bought overseas in 2015, excluding the typical pharma/biotech rights and licensing deals. We’ve seen 13 acquisitions of foreign companies so far, better than the 10 recorded in the same period in 2014. In the first two months of this year, $2.3 billion has been committed to those transactions. See the chart below. Read More »